Efficacy of short-term Peg-IFN α-2b treatment in chronic hepatitis B patients with ultra-low HBsAg levels: a retrospective cohort study
Our findings confirm that a 24-week course of Peg-IFN α-2b yields robust efficacy in CHB patients with ultra-low HBsAg levels. Prolonging treatment beyond the 24-week threshold is deemed unnecessary. Both baseline HBsAg level and the presence of fatty liver emerged as significant predictors for HBsAg clearance.
Authors
- C C Li
- Zhenjie Ma
- Siqi Yang
- Weixing Wang (ORCID: https://orcid.org/0000-0001-7044-2275)
- Yuying Li (ORCID: https://orcid.org/0000-0003-0165-8018)
- Mengmeng Zhang (ORCID: https://orcid.org/0000-0001-7632-7702)
- Haiyan Hou (ORCID: https://orcid.org/0000-0002-3052-1259)
- Liying Zhu (ORCID: https://orcid.org/0000-0002-2037-1269)
- Wenhang Zou
- Zihao Wu
Institutions
- Harbin Medical University (CN)
- Wuhan University (CN)
- Third Affiliated Hospital of Harbin Medical University (CN)
- Second Affiliated Hospital of Harbin Medical University (CN)
- Renmin Hospital of Wuhan University (CN)
Publication Details
- Journal
- Virology Journal
- Published
- 2024-09-27
- DOI
- https://doi.org/10.1186/s12985-024-02512-w
- Citations
- 7
- Primary Topic
- Hepatitis B Virus Studies
- Type
- article
- Field-Weighted Citation Impact
- 2.71